Barclays analyst Carter Gould lowered the firm’s price target on Regeneron Pharmaceuticals to $888 from $915 and keeps an Overweight rating on the shares. The Complete Response Letter for high dose Eylea likely pushes out approval “a matter of months,” the analyst tells investor sin a research note. The firm now assumes a Q4 approval and July 2024 J-code.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on REGN:
- REGN, CTLT Continue Sliding Following FDA Rejection of Eylea Drug
- Regeneron downgraded to Hold from Buy at Canaccord
- Regeneron Stock (NASDAQ:REGN) Sinks; FDA Snubs Higher-Dose Eye Drug
- Morgan Stanley says Regeneron likely to come under pressure after surprising CRL
- Regeneron resumes, down 9% after CRL issued for aflibercept 8 mg BLA